N-(t-butoxycarbonyl)-L-phenylalanine methylamide | 109522-21-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-(t-butoxycarbonyl)-L-phenylalanine methylamide
• 英文别名: (S)-2-N-boc-N-methyl-3-phenylpropanamide；((1S)-1-Methylcarbamoyl-2-phenyl-ethyl)-carbamic acid tert-butyl ester；tert-butyl N-[(2S)-1-(methylamino)-1-oxo-3-phenylpropan-2-yl]carbamate
• CAS: 109522-21-6
• 化学式: C₁₅H₂₂N₂O₃
• 分子量: 278.351
• InChiKey: IAIKAKWKWIJNAO-LBPRGKRZSA-N

物化性质

• 熔点：
  142-143 °C(Solv: ethyl acetate (141-78-6); pentane (109-66-0))
• 沸点：
  483.5±45.0 °C(Predicted)
• 密度：
  1.085±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  20
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  67.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-(t-butoxycarbonyl)-L-phenylalanine methylamide 在 盐酸 作用下， 以 1,4-二氧六环 为溶剂， 反应 1.0h， 生成 L-苯基丙氨酸甲酰胺
  参考文献：
  名称：

  New hydroxyethylamine HIV protease inhibitors that suppress viral replication

  摘要：

  The synthesis of analogues of AcSerLeuAsn[Phe-HEA-Pro]IleValOMe (1, JG-365; where HEA stands for the hydroxyethylamine unit 2), a tight-binding inhibitor of HIVP, are reported. Systematic modification of the P3 and P3' regions of the inhibitors has led to smaller HIVP inhibitors that inhibit viral replication in HIV-infected and SIV-infected cell cultures. Six aliphatic and/or aromatic derivatives were prepared by replacing residues in the P3 regions of BocLeuAsn[Phe-HEA-Pro]IleValOMe. Aromatic side chains at P3 gave better inhibitors than aliphatic side chains. The better inhibitors in this series contained a beta-naphthylalanine or a biphenyl unit at P3. A second series of HIVP inhibitors were obtained by converting the P3 group into acyl groups. CbzAsn[Phe-HEA-Pro]IlePheOMe and Qua-Asn-[Phe-HEA-Pro]-Ile-Phe-OMe (where Qua = quinolin-2-ylcarbonyl) are potent HIVP inhibitors with K(i) values equal to 1.0 and 0.1 nM, respectively. The inhibition constants were determined by using the continuous fluorometric assay developed by Toth and Marshall. The activities of the protease inhibitors for inhibition of SIV replication were determined in vitro using CEMX174 cells. Inhibition of HIV infection was determined essentially as reported by Pauwels and co-workers. The anti-HIV assay was carried out in culture using CEM cell (a CD4+ lymphocyte line) infected with virus strain HTLV-IIIb with a multiplicity of infection of 0.1. Several analogues inhibited the cytopathic effect at concentrations of 0.1-0.8 mug/mL. These results establish that good inhibitors of HIV protease that inhibit viral replication in infected lymphocytes in in vitro cell assays can be obtained from JG-365 when the AcSerLeu unit is replaced by aromatic acyl derivatives.

  DOI：

  10.1021/jm00099a008
• 作为产物：
  描述：

  BOC-L-苯丙氨酸 在 盐酸甲胺 作用下， 生成 N-(t-butoxycarbonyl)-L-phenylalanine methylamide
  参考文献：
  名称：

  Substituted n-(indole-2-carbonyl)-glycinamides and derivatives as

  摘要：

  公式（1）的化合物，其中R6是羧基，（C1-C8）烷氧基羰基，苄氧基羰基，C(O)NR8R9或C(O)R12作为葡萄糖磷酸化酶抑制剂，包含此类抑制剂的药物组合物以及使用此类抑制剂治疗哺乳动物中的糖尿病、高血糖、高胆固醇血症、高血压、高胰岛素血症、高脂血症、动脉粥样硬化和心肌缺血。

  公开号：

  US06107329A1

文献信息

• NEW ANTIBODY DRUG CONJUGATES (ADCS) AND THE USE THEREOF
  申请人：SEATTLE GENETICS, INC.

  公开号：US20150023989A1

  公开（公告）日：2015-01-22

  The present application relates to new antibody drug conjugates (ADCs) of N,N dialkylauristatins directed against the target FGFR2, drug metabolites of said ADCs, a method for producing said ADCs, the use of said ADCs for the treatment and/or prevention of illnesses as well as the use of said ADCs for producing pharmaceuticals for the treatment and/or prevention of illnesses, particularly of hyperproliferative and/or angiogenic diseases such as carcinosis. Such treatments can be carried out as monotherapy or in combination with other pharmaceuticals or additional therapeutic measures.

  本申请涉及针对FGFR2靶点的新抗体药物结合物（ADCs），所述ADCs的药物代谢产物，生产所述ADCs的方法，利用所述ADCs治疗和/或预防疾病以及利用所述ADCs生产用于治疗和/或预防疾病的药物，特别是治疗高增殖和/或血管生成性疾病如癌症。这种治疗可以作为单药疗法进行，也可以与其他药物或额外的治疗措施结合使用。
• NOVEL BINDER-DRUG CONJUGATES (ADCs) AND USE OF SAME
  申请人：SEATTLE GENETICS, INC.

  公开号：US20150246136A1

  公开（公告）日：2015-09-03

  The present patent application relates to novel binder-drug conjugates (ADCs) of N,N-dialkylauristatins directed against the target epidermal growth factor receptor (EGFR, gene ID 1956), effective metabolites of these ADCs, methods for producing these ADCs, use of these ADCs for treatment and or prevention of diseases as well as the use of these ADCs to produce pharmaceutical drugs for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic diseases such as cancer, for example. Such treatments may be administered as monotherapy or in combination with other pharmaceutical drugs or other therapeutic measures.

  本专利申请涉及针对靶向表皮生长因子受体（EGFR，基因ID 1956）的新型结合物-药物共轭物（ADCs）N，N-二烷基月桂酰基蛋白酶抑制剂，这些ADCs的有效代谢物，生产这些ADCs的方法，利用这些ADCs治疗和/或预防疾病，以及利用这些ADCs生产用于治疗和/或预防疾病的药物，特别是治疗高增殖和/或血管生成性疾病，如癌症。这种治疗可以作为单药疗法或与其他药物或其他治疗措施联合使用。
• Competitive formation of 10- and 7-membered hydrogen-bonded rings of proline-containing model peptides
  作者：Yusuke Jin、Kenji Tonan、Shun-ichi Ikawa

  DOI：10.1016/s1386-1425(02)00031-8

  日期：2002.10

  N-tert-butoxycarbonyl-prolyl-Xaa-NHCH3 [Xaa = Gly (glycyl), Ala (alanyl), Phe (phenylalanyl), Leu (leucyl), Ile (isoleucyl), and Val (valyl)] were studied by proton nuclear magnetic resonance and infrared spectroscopy. Variation of chemical shifts of amide protons with composition change of DMSO-d6/CDCl3 mixed solvents were found to be a good measure of intramolecular hydrogen bonding of peptides in CDCl3

  含有脯氨酸的模型肽的分子内氢键结构，具有序列N-叔丁氧基羰基-脯氨酰基-Xaa-NHCH3 [Xaa =甘氨酸（甘氨酰基），丙氨酸（丙氨酰基），苯丙氨酸（苯丙氨酰基），亮（甘氨酸），胰岛通过异质子核磁共振和红外光谱研究了（异sole基）和Val（戊基）。发现酰胺质子化学位移随DMSO-d6 / CDCl3混合溶剂组成的变化而变化，是衡量CDCl3溶液中肽的分子内氢键的好方法。已经显示，在蛋白质中应分别具有β-和γ-转角样结构的10元和7元氢键合的环彼此竞争地形成。建议两个氢键合的环之间的平衡由Xaa残基的侧链所引起的位阻决定。从化学位移的溶剂组成依赖性变化估计形成10元和7元氢键环的自由能delG10和delG7。已发现deltaG10与蛋白质β转换的第（i + 2）位残基Xaa的出现频率之间具有良好的相关性。
• N-carboxymethyl substituted benzolactams as inhibitors of matrix metalloproteinase
  申请人：——

  公开号：US20020095035A1

  公开（公告）日：2002-07-18

  The present invention provides a method of inhibiting matrix metallo-proteinases (MMPs) in a patient in need thereof comprising administering to the patient an effective matrix metalloproteinase inhibiting amount of the N-carboxymethyl substituted benzolactams of formula (1): 1 wherein A is —OH or —NRR′. Such inhibitors are useful in treating neoplasms, atherosclorosis, and chronic inflammatory diseases. The present invention also provides novel N-carboxymethyl substituted benzolactams of formula (1a): 2 wherein A is —NRR′.

  本发明提供了一种抑制需要患者体内基质金属蛋白酶（MMPs）的方法，包括向患者施用N-羧甲基取代苯并内酰胺的有效基质金属蛋白酶抑制剂量，其化学式为（1）： 1 其中A为—OH或—NRR′。这些抑制剂在治疗肿瘤、动脉粥样硬化和慢性炎症性疾病方面是有用的。 本发明还提供了新颖的化学式（1a）中A为—NRR′的N-羧甲基取代苯并内酰胺。
• Selective inhibitors of MMP-12
  申请人：Aventis Pharmaceuticals Inc.

  公开号：US06352976B1

  公开（公告）日：2002-03-05

  The present invention provides novel mercaptoacetylamido dipeptide carboxylic acids of the formula which are MMP inhibitors useful for the treatment of smoking-induced emphysema.

  本发明提供了一种新型的巯基乙酰胺二肽羧酸，其化学式为，这些是对治疗吸烟引起的肺气肿有用的MMP抑制剂。